Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 13/20 | 0.41 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.40 |
| ▸ | MICA | Q29983 | 2/20 | 0.40 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.40 |
| ▸ | APOB | P04114 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Granotapide SCHEMBL1484041 | 0.94 | MTTP (0.44) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL3737499 | 0.94 | MTTP (0.42) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL3727332 | 0.93 | MTTP (0.40) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL3726255 | 0.92 | MTTP (0.41) | MTTPKLRK1MICARAET1LRXFP1 | |
| SCHEMBL3730523 | 0.91 | MTTP (0.39) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL3722379 | 0.91 | KLRK1 (0.44) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL3722420 | 0.91 | MTTP (0.39) | MTTPKLRK1MICARAET1LRXFP1 | |
| SCHEMBL3727097 | 0.90 | MTTP (0.44) | MTTPAPOBRXFP1 | |
| SCHEMBL14031595 | 0.90 | MTTP (0.43) | MTTPKLRK1MICARAET1LAPOB | |
| SCHEMBL3723799 | 0.90 | MTTP (0.45) | MTTPKLRK1MICARAET1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | claimed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | claimed |
| US-20060153913-A1 | Solid formulation with improved solubility and stability, and method for producing said formulation | JAPAN TOBACCO INC. (JP) | 2006-07-13 | — | — | US | claimed |
| US-20050075367-A1 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | US | claimed |
| EP-1479666-A1 | ESTER COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-11-24 | — | — | EP | claimed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | disclosed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| EP-1806149-A1 | SOLID MEDICINAL PREPARATION IMPROVED IN SOLUBILITY AND STABILITY AND PROCESS FOR PRODUCING THE SAME | Japan Tobacco, Inc. (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20060153913-A1 | Solid formulation with improved solubility and stability, and method for producing said formulation | JAPAN TOBACCO INC. (JP) | 2006-07-13 | — | — | US | disclosed |
| US-20050075367-A1 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | US | disclosed |
| EP-1479666-A1 | ESTER COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075367-A1 | Ester compound and medicinal use thereof | LIPC, CES1, MTTP | MTTP 3/4885KLRK1 3360/4885MICA 3630/4885 |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | LIPC, CES1, MTTP | MTTP 3/4885KLRK1 3855/4885MICA 3640/4885 |
| US-20060153913-A1 | Solid formulation with improved solubility and stability, and method for producing said formulation | ABCG2, SORD, SRI | MTTP 1276/4885KLRK1 1076/4885MICA 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.